Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Up 1,956.5% in January

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 141,900 shares, a growth of 1,956.5% from the December 31st total of 6,900 shares. Based on an average daily volume of 503,100 shares, the short-interest ratio is presently 0.3 days. Approximately 5.2% of the company’s stock are short sold.

Traws Pharma Price Performance

Shares of Traws Pharma stock remained flat at $7.38 during trading hours on Wednesday. The stock had a trading volume of 85,046 shares, compared to its average volume of 153,010. The company has a market cap of $26.94 million, a P/E ratio of -0.05 and a beta of 1.13. Traws Pharma has a 1-year low of $4.06 and a 1-year high of $27.50. The stock has a 50-day moving average of $6.73.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.